Cooley advised RAPT Therapeutics (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases, on its definitive agreement to be acquired by GSK. Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58 per share in cash at closing for an estimated aggregate equity value of $2.2 billion.